USpharma, a pharmaceutical development and manufacturing company recognized for its innovative delivery platforms, has announced a substantial growth equity investment from 1315 Capital, a healthcare-focused growth equity firm based in Philadelphia.
USpharma utilizes advanced and patented formulation technologies, including next-generation soft chewable dosage forms, and leverages the unique capabilities of its 150,000-square-foot GMP-compliant facility located in the United States.
These technologies enable the development and manufacture of innovative products across various pharmaceutical and supplement markets. The capital infusion will facilitate USpharma’s acceleration of pipeline development and commercialization, as well as scaling operations to address increasing market demand.
KEY QUOTES:
“We are thrilled to partner with 1315 Capital as we enter this pivotal stage of growth. This investment allows us to advance our mission to deliver science-backed, high-quality health solutions that improve patient access and adherence. We’re excited to bring our next-generation products to a broader audience with the support of such an experienced partner.”
Manesh Dixit, Ph.D., Chief Executive Officer of USpharma
“Consumers are increasingly focused on health and wellness solutions that are not only efficacious but delivered in a format that fits with their preferences and lifestyle. We are proud to partner with USpharma as they expand their commercial reach and provide compelling product formulations in numerous large and growing healthcare markets.”
Matthew Reber, Partner at 1315 Capital
